Table 1.
Clinicopathological characteristics of patients before and after propensity score matching.
| Variables | Before propensity score matching | After propensity score matching | ||||
|---|---|---|---|---|---|---|
| Low AST/ALT (N = 466) | High AST/ALT (N = 305) | P value | Low AST/ALT (N = 305) | High AST/ALT (N = 305) | P value | |
| Mean age (year) | 62.9 ± 9.9 | 67.2 ± 10.0 | <0.001 | 64.6 ± 8.8 | 67.2 ± 10.0 | 0.001 |
| Gender | <0.001 | <0.001 | ||||
| Female | 45 (9.6%) | 74 (24.3%) | 31 (10.2%) | 74 (24.3%) | ||
| Male | 421 (90.4%) | 231 (75.7%) | 274 (89.8%) | 231 (75.7%) | ||
| BMI (kg/m2) | 23.7 ± 3.8 | 22.2 ± 2.9 | <0.001 | 23.0 ± 2.7 | 22.2 ± 2.9 | 0.067 |
| ASA | 0.373 | 0.714 | ||||
| 1 | 172 (36.9%) | 103 (33.7%) | 110 (36.0%) | 103 (33.7%) | ||
| 2 | 275 (59.0%) | 182 (59.7%) | 180 (59.0%) | 182 (59.7%) | ||
| ≥3 | 19 (4.1%) | 20 (6.6%) | 15 (4.9%) | 20 (6.6%) | ||
| Operative type | 0.218 | 0.273 | ||||
| Open | 424 (91.0%) | 285 (93.5%) | 295 (93.4%) | 285 (93.5%) | ||
| Laparoscopic | 24 (5.2%) | 16 (5.2%) | 11 (3.6%) | 16 (5.2%) | ||
| Robot | 18 (3.8%) | 4 (1.3%) | 9 (3.0%) | 4 (1.3%) | ||
| Diversion type | 0.052 | 0.168 | ||||
| Conduit | 253 (54.3%) | 194 (63.6%) | 209 (68.5%) | 194 (63.6%) | ||
| Neobladder | 213 (45.7%) | 111 (36.4%) | 96 (31.5%) | 111 (36.4%) | ||
| Tumor grade | 0.396 | 0.569 | ||||
| Low | 12 (2.6%) | 11 (3.6%) | 10 (3.3%) | 11 (3.6%) | ||
| High | 454 (97.4%) | 294 (96.4%) | 295 (96.7%) | 294 (96.4%) | ||
| Tumor size (cm) | 2.4 ± 3.0 | 3.3 ± 3.2 | 0.017 | 1.2 ± 2.4 | 3.3 ± 3.2 | 0.058 |
| Pathological T stage | 0.002 | 0.112 | ||||
| T1 | 73 (15.7%) | 57 (18.7%) | 53 (17.4%) | 57 (18.7%) | ||
| T2 | 264 (56.7%) | 122 (40.0%) | 156 (51.0%) | 122 (40.1%) | ||
| T3 | 106 (22.7%) | 104 (34.1%) | 80 (26.2%) | 104 (34.1%) | ||
| T4 | 23 (4.9%) | 22 (7.2%) | 16 (5.2%) | 22 (7.2%) | ||
| Margin positive | 7 (1.5%) | 15 (4.9%) | 0.036 | 5 (1.6%) | 15 (4.9%) | 0.041 |
| LVI | 129 (27.6%) | 106 (34.8%) | 0.055 | 90 (29.5%) | 106 (34.8%) | 0.193 |
| CIS | 155 (33.3%) | 97 (31.8%) | 0.735 | 97 (31.8%) | 97 (31.8%) | 1.000 |
| Pathological N stage | 0.455 | 0.544 | ||||
| N0 | 382 (82.0%) | 240 (78.7%) | 252 (82.6%) | 240 (78.7%) | ||
| N1 | 34 (7.3%) | 20 (6.6%) | 20 (6.6%) | 20 (6.6%) | ||
| N2 | 42 (9.0%) | 38 (12.5%) | 28 (9.2%) | 38 (12.5%) | ||
| N3 | 8 (1.7%) | 7 (2.3%) | 5 (1.6%) | 7 (2.3%) | ||
| Removed LN | 18.9 ± 11.7 | 16.9 ± 10.9 | 0.018 | 17.1 ± 11.5 | 16.9 ± 10.9 | 0.158 |
| Positive LN | 0.7 ± 2.5 | 1.0 ± 3.0 | 0.199 | 0.6 ± 2.3 | 1.0 ± 3.0 | 0.146 |
| Pathological M stage | 0.749 | 0.966 | ||||
| M0 | 462 (99.2%) | 304 (99.7%) | 363 (99.2%) | 304 (99.7%) | ||
| M1 | 4 (0.8%) | 1 (0.3%) | 2 (0.7%) | 1 (0.3%) | ||
| NACH | 64 (13.7%) | 39 (12.8%) | 0.827 | 40 (13.1%) | 39 (12.8%) | 0.976 |
| ACH | 99 (21.2%) | 74 (24.3%) | 0.414 | 65 (21.3%) | 74 (24.3%) | 0.440 |
| ART | 4 (0.8%) | 3 (1.0%) | 0.986 | 3 (1.0%) | 3 (1.0%) | 1.000 |
| Recurrence rate | 139 (29.8%) | 115 (37.7%) | 0.037 | 89 (29.2%) | 115 (37.7%) | 0.032 |
| Mortality | 141 (30.3%) | 140 (45.9%) | <0.001 | 96 (31.5%) | 140 (45.9%) | <0.001 |
| Cancer-caused mortality | 88 (18.9%) | 96 (31.5%) | <0.001 | 59 (19.3%) | 96 (31.5%) | 0.001 |
| AST/ALT ratio | 0.9 ± 0.2 | 1.7 ± 1.6 | <0.001 | 0.9 ± 0.2 | 1.7 ± 1.6 | <0.001 |
ASA: American Society of Anesthesiologists; BMI: body mass index; NACH: neoadjuvant chemotherapy; ALT: alanine aminotransferase; AST: aspartate aminotransferase; LVI: lymphovascular invasion; CIS: carcinoma in situ; LN: lymph node; NACH: neoadjuvant chemotherapy; ACH: adjuvant chemotherapy; ART: adjuvant radiotherapy.